KR20040049294A - 아미노산 킬레이트의 제조방법 - Google Patents
아미노산 킬레이트의 제조방법 Download PDFInfo
- Publication number
- KR20040049294A KR20040049294A KR1020030088214A KR20030088214A KR20040049294A KR 20040049294 A KR20040049294 A KR 20040049294A KR 1020030088214 A KR1020030088214 A KR 1020030088214A KR 20030088214 A KR20030088214 A KR 20030088214A KR 20040049294 A KR20040049294 A KR 20040049294A
- Authority
- KR
- South Korea
- Prior art keywords
- calcium
- carbonate
- amino acid
- metal
- sulfate
- Prior art date
Links
- 239000013522 chelant Substances 0.000 title claims abstract description 104
- 150000001413 amino acids Chemical class 0.000 title claims abstract description 100
- 238000000034 method Methods 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims description 26
- 235000001014 amino acid Nutrition 0.000 claims abstract description 105
- 238000006243 chemical reaction Methods 0.000 claims abstract description 87
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 84
- 239000000203 mixture Substances 0.000 claims abstract description 67
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims abstract description 42
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 39
- 229910021645 metal ion Inorganic materials 0.000 claims abstract description 37
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims abstract description 34
- 239000004220 glutamic acid Substances 0.000 claims abstract description 33
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims abstract description 32
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims abstract description 29
- 235000013922 glutamic acid Nutrition 0.000 claims abstract description 29
- 235000003704 aspartic acid Nutrition 0.000 claims abstract description 17
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 230000002378 acidificating effect Effects 0.000 claims abstract description 13
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 claims abstract description 9
- 239000011667 zinc carbonate Substances 0.000 claims abstract description 9
- 235000004416 zinc carbonate Nutrition 0.000 claims abstract description 9
- 229910000010 zinc carbonate Inorganic materials 0.000 claims abstract description 9
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims abstract description 4
- 239000001095 magnesium carbonate Substances 0.000 claims abstract description 4
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims abstract description 4
- XHFVDZNDZCNTLT-UHFFFAOYSA-H chromium(3+);tricarbonate Chemical compound [Cr+3].[Cr+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O XHFVDZNDZCNTLT-UHFFFAOYSA-H 0.000 claims abstract description 3
- 229910021446 cobalt carbonate Inorganic materials 0.000 claims abstract description 3
- ZOTKGJBKKKVBJZ-UHFFFAOYSA-L cobalt(2+);carbonate Chemical compound [Co+2].[O-]C([O-])=O ZOTKGJBKKKVBJZ-UHFFFAOYSA-L 0.000 claims abstract description 3
- 229940116318 copper carbonate Drugs 0.000 claims abstract description 3
- GEZOTWYUIKXWOA-UHFFFAOYSA-L copper;carbonate Chemical compound [Cu+2].[O-]C([O-])=O GEZOTWYUIKXWOA-UHFFFAOYSA-L 0.000 claims abstract description 3
- RAQDACVRFCEPDA-UHFFFAOYSA-L ferrous carbonate Chemical compound [Fe+2].[O-]C([O-])=O RAQDACVRFCEPDA-UHFFFAOYSA-L 0.000 claims abstract description 3
- 239000011656 manganese carbonate Substances 0.000 claims abstract description 3
- 235000006748 manganese carbonate Nutrition 0.000 claims abstract description 3
- 229940093474 manganese carbonate Drugs 0.000 claims abstract description 3
- 229910000016 manganese(II) carbonate Inorganic materials 0.000 claims abstract description 3
- XMWCXZJXESXBBY-UHFFFAOYSA-L manganese(ii) carbonate Chemical compound [Mn+2].[O-]C([O-])=O XMWCXZJXESXBBY-UHFFFAOYSA-L 0.000 claims abstract description 3
- 239000011575 calcium Substances 0.000 claims description 143
- 229910052791 calcium Inorganic materials 0.000 claims description 105
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 104
- 229940024606 amino acid Drugs 0.000 claims description 99
- 229910052751 metal Inorganic materials 0.000 claims description 68
- 239000002184 metal Substances 0.000 claims description 68
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 52
- 235000010216 calcium carbonate Nutrition 0.000 claims description 39
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 24
- 229940009098 aspartate Drugs 0.000 claims description 21
- 241001474374 Blennius Species 0.000 claims description 20
- -1 magnesium bisglutamate amino acid Chemical class 0.000 claims description 14
- 235000013305 food Nutrition 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 10
- 239000007864 aqueous solution Substances 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 10
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 8
- UIOULKWHZFUGJO-DFWYDOINSA-N (2s)-2-aminopentanedioic acid;iron Chemical compound [Fe].OC(=O)[C@@H](N)CCC(O)=O UIOULKWHZFUGJO-DFWYDOINSA-N 0.000 claims description 7
- 235000013361 beverage Nutrition 0.000 claims description 7
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims description 7
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 7
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 7
- 229960001763 zinc sulfate Drugs 0.000 claims description 7
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims description 6
- 239000002537 cosmetic Substances 0.000 claims description 6
- 229910000358 iron sulfate Inorganic materials 0.000 claims description 6
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims description 6
- 235000016709 nutrition Nutrition 0.000 claims description 6
- 229910000365 copper sulfate Inorganic materials 0.000 claims description 5
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 claims description 5
- 229940099596 manganese sulfate Drugs 0.000 claims description 5
- 239000011702 manganese sulphate Substances 0.000 claims description 5
- 235000007079 manganese sulphate Nutrition 0.000 claims description 5
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 claims description 5
- YVHGUOMYKODENE-QHTZZOMLSA-J (2S)-2-aminopentanedioate chromium(4+) Chemical compound [Cr+4].[O-]C(=O)[C@@H](N)CCC([O-])=O.[O-]C(=O)[C@@H](N)CCC([O-])=O YVHGUOMYKODENE-QHTZZOMLSA-J 0.000 claims description 4
- NKKATTXYBIGWMW-PREAGGAWSA-H N[C@@H](CCC(=O)[O-])C(=O)[O-].[Cr+3].N[C@@H](CCC(=O)[O-])C(=O)[O-].N[C@@H](CCC(=O)[O-])C(=O)[O-].[Cr+3] Chemical compound N[C@@H](CCC(=O)[O-])C(=O)[O-].[Cr+3].N[C@@H](CCC(=O)[O-])C(=O)[O-].N[C@@H](CCC(=O)[O-])C(=O)[O-].[Cr+3] NKKATTXYBIGWMW-PREAGGAWSA-H 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 4
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 102000002322 Egg Proteins Human genes 0.000 claims description 3
- 108010000912 Egg Proteins Proteins 0.000 claims description 3
- DYNAPBNBYCFIJB-QHTZZOMLSA-J [Cu+4].[O-]C(=O)[C@@H](N)CCC([O-])=O.[O-]C(=O)[C@@H](N)CCC([O-])=O Chemical compound [Cu+4].[O-]C(=O)[C@@H](N)CCC([O-])=O.[O-]C(=O)[C@@H](N)CCC([O-])=O DYNAPBNBYCFIJB-QHTZZOMLSA-J 0.000 claims description 3
- RYVCHORNKKBBJW-QHTZZOMLSA-J [Fe+4].[O-]C(=O)[C@@H](N)CCC([O-])=O.[O-]C(=O)[C@@H](N)CCC([O-])=O Chemical compound [Fe+4].[O-]C(=O)[C@@H](N)CCC([O-])=O.[O-]C(=O)[C@@H](N)CCC([O-])=O RYVCHORNKKBBJW-QHTZZOMLSA-J 0.000 claims description 3
- GRWVQDDAKZFPFI-UHFFFAOYSA-H chromium(III) sulfate Chemical compound [Cr+3].[Cr+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRWVQDDAKZFPFI-UHFFFAOYSA-H 0.000 claims description 3
- JVKRVCJEGVAHAO-OYIAIMIOSA-J dimagnesium (2S)-2-aminopentanedioate Chemical compound [Mg+2].[Mg+2].[O-]C(=O)[C@@H](N)CCC([O-])=O.[O-]C(=O)[C@@H](N)CCC([O-])=O JVKRVCJEGVAHAO-OYIAIMIOSA-J 0.000 claims description 3
- 210000003278 egg shell Anatomy 0.000 claims description 3
- 229930195712 glutamate Natural products 0.000 claims description 3
- CFSIMSPVBRMSRX-DFWYDOINSA-L (2s)-2-aminopentanedioate;manganese(2+) Chemical compound [Mn+2].[O-]C(=O)[C@@H](N)CCC([O-])=O CFSIMSPVBRMSRX-DFWYDOINSA-L 0.000 claims description 2
- 241000238371 Sepiidae Species 0.000 claims description 2
- SQLZCNCPUNKHPX-CEOVSRFSSA-J [Cr+4].[O-]C(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC([O-])=O Chemical compound [Cr+4].[O-]C(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC([O-])=O SQLZCNCPUNKHPX-CEOVSRFSSA-J 0.000 claims description 2
- MUARKRXWUCMPOS-CEOVSRFSSA-J [Mn+4].[O-]C(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC([O-])=O Chemical compound [Mn+4].[O-]C(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC([O-])=O MUARKRXWUCMPOS-CEOVSRFSSA-J 0.000 claims description 2
- GLTMXYSRENMKGS-QHTZZOMLSA-J [Mn+4].[O-]C(=O)[C@@H](N)CCC([O-])=O.[O-]C(=O)[C@@H](N)CCC([O-])=O Chemical compound [Mn+4].[O-]C(=O)[C@@H](N)CCC([O-])=O.[O-]C(=O)[C@@H](N)CCC([O-])=O GLTMXYSRENMKGS-QHTZZOMLSA-J 0.000 claims description 2
- JHFLVJIIPLMGMD-NVKWYWNSSA-J [Zn+2].[Zn+2].[O-]C(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC([O-])=O Chemical compound [Zn+2].[Zn+2].[O-]C(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC([O-])=O JHFLVJIIPLMGMD-NVKWYWNSSA-J 0.000 claims description 2
- 235000013921 calcium diglutamate Nutrition 0.000 claims description 2
- UMVAYAXXQSFULN-QHTZZOMLSA-L calcium;(2s)-2-aminopentanedioate;hydron Chemical group [Ca+2].[O-]C(=O)[C@@H](N)CCC(O)=O.[O-]C(=O)[C@@H](N)CCC(O)=O UMVAYAXXQSFULN-QHTZZOMLSA-L 0.000 claims description 2
- 229910000361 cobalt sulfate Inorganic materials 0.000 claims description 2
- 229940044175 cobalt sulfate Drugs 0.000 claims description 2
- KTVIXTQDYHMGHF-UHFFFAOYSA-L cobalt(2+) sulfate Chemical compound [Co+2].[O-]S([O-])(=O)=O KTVIXTQDYHMGHF-UHFFFAOYSA-L 0.000 claims description 2
- SSFMKHSRFMRWFB-NVKWYWNSSA-J dicalcium (2S)-2-aminobutanedioate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC([O-])=O SSFMKHSRFMRWFB-NVKWYWNSSA-J 0.000 claims description 2
- QIWQPDUTCBLMSG-OYIAIMIOSA-J dicalcium (2S)-2-aminopentanedioate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)[C@@H](N)CCC([O-])=O.[O-]C(=O)[C@@H](N)CCC([O-])=O QIWQPDUTCBLMSG-OYIAIMIOSA-J 0.000 claims description 2
- UPXURESQFGNHFF-OYIAIMIOSA-J dizinc (2S)-2-aminopentanedioate Chemical compound [Zn+2].[Zn+2].[O-]C(=O)[C@@H](N)CCC([O-])=O.[O-]C(=O)[C@@H](N)CCC([O-])=O UPXURESQFGNHFF-OYIAIMIOSA-J 0.000 claims description 2
- 229960001983 magnesium aspartate Drugs 0.000 claims description 2
- 235000013918 magnesium diglutamate Nutrition 0.000 claims description 2
- 229940063886 magnesium glutamate Drugs 0.000 claims description 2
- MYUGVHJLXONYNC-QHTZZOMLSA-J magnesium;(2s)-2-aminopentanedioate Chemical compound [Mg+2].[O-]C(=O)[C@@H](N)CCC([O-])=O.[O-]C(=O)[C@@H](N)CCC([O-])=O MYUGVHJLXONYNC-QHTZZOMLSA-J 0.000 claims description 2
- GAMIYQSIKAOVTG-UHFFFAOYSA-L zinc;2-aminopentanedioate Chemical compound [Zn+2].[O-]C(=O)C(N)CCC([O-])=O GAMIYQSIKAOVTG-UHFFFAOYSA-L 0.000 claims description 2
- 229910021653 sulphate ion Inorganic materials 0.000 claims 2
- QYPQOBGSGQXODC-DFWYDOINSA-N (2s)-2-aminopentanedioic acid;cobalt Chemical compound [Co].OC(=O)[C@@H](N)CCC(O)=O QYPQOBGSGQXODC-DFWYDOINSA-N 0.000 claims 1
- VPJTZLCWKQAMFA-NYIJDJKZSA-N (2s)-2-azanylbutanedioic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O.OC(=O)[C@@H](N)CC(O)=O.OC(=O)[C@@H](N)CC(O)=O VPJTZLCWKQAMFA-NYIJDJKZSA-N 0.000 claims 1
- FBGXTRRWTIVJSK-OYIAIMIOSA-J N[C@@H](CCC(=O)[O-])C(=O)[O-].N[C@@H](CCC(=O)[O-])C(=O)[O-].[Fe+2].[Fe+2] Chemical compound N[C@@H](CCC(=O)[O-])C(=O)[O-].N[C@@H](CCC(=O)[O-])C(=O)[O-].[Fe+2].[Fe+2] FBGXTRRWTIVJSK-OYIAIMIOSA-J 0.000 claims 1
- PKVKODBXRPUCJI-CEOVSRFSSA-J [Cu+4].[O-]C(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC([O-])=O Chemical compound [Cu+4].[O-]C(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC([O-])=O PKVKODBXRPUCJI-CEOVSRFSSA-J 0.000 claims 1
- DSNHOAHGBPRRMT-CEOVSRFSSA-J [Fe+4].[O-]C(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC([O-])=O Chemical compound [Fe+4].[O-]C(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC([O-])=O DSNHOAHGBPRRMT-CEOVSRFSSA-J 0.000 claims 1
- HIAAPJWEVOPQRI-DFWYDOINSA-L copper;(2s)-2-aminopentanedioate Chemical compound [Cu+2].[O-]C(=O)[C@@H](N)CCC([O-])=O HIAAPJWEVOPQRI-DFWYDOINSA-L 0.000 claims 1
- IACWRJKFRODGGM-NVKWYWNSSA-J dimagnesium (2S)-2-aminobutanedioate Chemical compound [Mg+2].[Mg+2].[O-]C(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC([O-])=O IACWRJKFRODGGM-NVKWYWNSSA-J 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 19
- 235000019640 taste Nutrition 0.000 abstract description 14
- 230000000704 physical effect Effects 0.000 abstract description 4
- 239000004277 Ferrous carbonate Substances 0.000 abstract 1
- 229960003563 calcium carbonate Drugs 0.000 abstract 1
- 235000019268 ferrous carbonate Nutrition 0.000 abstract 1
- 229960004652 ferrous carbonate Drugs 0.000 abstract 1
- 229910000015 iron(II) carbonate Inorganic materials 0.000 abstract 1
- 229940043825 zinc carbonate Drugs 0.000 abstract 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 87
- 229910052742 iron Inorganic materials 0.000 description 42
- 239000000243 solution Substances 0.000 description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 38
- 238000003756 stirring Methods 0.000 description 30
- 239000006228 supernatant Substances 0.000 description 24
- 229910052500 inorganic mineral Inorganic materials 0.000 description 23
- 235000010755 mineral Nutrition 0.000 description 23
- 239000011707 mineral Substances 0.000 description 23
- 238000010521 absorption reaction Methods 0.000 description 20
- 235000005911 diet Nutrition 0.000 description 19
- 230000037213 diet Effects 0.000 description 19
- 238000005119 centrifugation Methods 0.000 description 18
- 230000002950 deficient Effects 0.000 description 17
- 241000195493 Cryptophyta Species 0.000 description 15
- 150000003278 haem Chemical group 0.000 description 14
- 239000002244 precipitate Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 229940069978 calcium supplement Drugs 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 239000011701 zinc Substances 0.000 description 10
- 229910052725 zinc Inorganic materials 0.000 description 10
- 206010022971 Iron Deficiencies Diseases 0.000 description 9
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 9
- 210000000988 bone and bone Anatomy 0.000 description 9
- 229940106635 calcium amino acid chelate Drugs 0.000 description 9
- UOXSXMSTSYWNMH-UHFFFAOYSA-L zinc;2-aminoacetate Chemical compound [Zn+2].NCC([O-])=O.NCC([O-])=O UOXSXMSTSYWNMH-UHFFFAOYSA-L 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 239000006227 byproduct Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 210000002082 fibula Anatomy 0.000 description 8
- 230000007935 neutral effect Effects 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 8
- 230000009469 supplementation Effects 0.000 description 8
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 239000011777 magnesium Substances 0.000 description 7
- 229910052749 magnesium Inorganic materials 0.000 description 7
- 229940091250 magnesium supplement Drugs 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 239000013589 supplement Substances 0.000 description 7
- 238000010171 animal model Methods 0.000 description 6
- 239000002738 chelating agent Substances 0.000 description 6
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 6
- 235000011194 food seasoning agent Nutrition 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 206010006956 Calcium deficiency Diseases 0.000 description 5
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 5
- 102000001554 Hemoglobins Human genes 0.000 description 5
- 108010054147 Hemoglobins Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 229910052804 chromium Inorganic materials 0.000 description 5
- 239000011651 chromium Substances 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000005534 hematocrit Methods 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- GYUKEMYHXWICKF-DKWTVANSSA-N (2s)-2-aminobutanedioic acid;calcium Chemical compound [Ca].OC(=O)[C@@H](N)CC(O)=O GYUKEMYHXWICKF-DKWTVANSSA-N 0.000 description 4
- LQZFQLVBZRVDLJ-DKWTVANSSA-N (2s)-2-aminobutanedioic acid;zinc Chemical compound [Zn].OC(=O)[C@@H](N)CC(O)=O LQZFQLVBZRVDLJ-DKWTVANSSA-N 0.000 description 4
- AXSWUQQYLYWEMJ-DFWYDOINSA-N (2s)-2-aminopentanedioic acid;calcium Chemical compound [Ca].OC(=O)[C@@H](N)CCC(O)=O AXSWUQQYLYWEMJ-DFWYDOINSA-N 0.000 description 4
- SYDXVIKBJDOFKI-DFWYDOINSA-N (2s)-2-aminopentanedioic acid;magnesium Chemical compound [Mg].OC(=O)[C@@H](N)CCC(O)=O SYDXVIKBJDOFKI-DFWYDOINSA-N 0.000 description 4
- RPDNPORXFSHJIY-DFWYDOINSA-N (2s)-2-aminopentanedioic acid;zinc Chemical compound [Zn].OC(=O)[C@@H](N)CCC(O)=O RPDNPORXFSHJIY-DFWYDOINSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000000292 calcium oxide Substances 0.000 description 4
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000002550 fecal effect Effects 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 230000001953 sensory effect Effects 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- XBJZQKABKZDDGY-DFWYDOINSA-N (2s)-2-aminopentanedioic acid;copper Chemical compound [Cu].OC(=O)[C@@H](N)CCC(O)=O XBJZQKABKZDDGY-DFWYDOINSA-N 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- JEEFUUDXSCMBKW-JIZZDEOASA-L C([O-])([O-])=O.[Ca+2].N[C@@H](CC(=O)O)C(=O)O Chemical compound C([O-])([O-])=O.[Ca+2].N[C@@H](CC(=O)O)C(=O)O JEEFUUDXSCMBKW-JIZZDEOASA-L 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 239000005862 Whey Substances 0.000 description 3
- 102000007544 Whey Proteins Human genes 0.000 description 3
- 108010046377 Whey Proteins Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229910017052 cobalt Inorganic materials 0.000 description 3
- 239000010941 cobalt Substances 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 229910052748 manganese Inorganic materials 0.000 description 3
- 239000011572 manganese Substances 0.000 description 3
- 235000015205 orange juice Nutrition 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000011573 trace mineral Substances 0.000 description 3
- 235000013619 trace mineral Nutrition 0.000 description 3
- PKQNYFAWUHYJOQ-DKWTVANSSA-N (2s)-2-aminobutanedioic acid;iron Chemical compound [Fe].OC(=O)[C@@H](N)CC(O)=O PKQNYFAWUHYJOQ-DKWTVANSSA-N 0.000 description 2
- GSNSYEWKUOGVHH-DFWYDOINSA-N (2s)-2-aminopentanedioic acid;chromium Chemical compound [Cr].OC(=O)[C@@H](N)CCC(O)=O GSNSYEWKUOGVHH-DFWYDOINSA-N 0.000 description 2
- GHRQAUKEGXIPPH-DFWYDOINSA-N (2s)-2-aminopentanedioic acid;manganese Chemical compound [Mn].OC(=O)[C@@H](N)CCC(O)=O GHRQAUKEGXIPPH-DFWYDOINSA-N 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- 239000004278 EU approved seasoning Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 102000008133 Iron-Binding Proteins Human genes 0.000 description 2
- 108010035210 Iron-Binding Proteins Proteins 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000007259 addition reaction Methods 0.000 description 2
- 235000008206 alpha-amino acids Nutrition 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 2
- 239000000920 calcium hydroxide Substances 0.000 description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 2
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 description 2
- 229960004874 choline bitartrate Drugs 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 238000002845 discoloration Methods 0.000 description 2
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229940049906 glutamate Drugs 0.000 description 2
- 239000007952 growth promoter Substances 0.000 description 2
- 238000009616 inductively coupled plasma Methods 0.000 description 2
- 235000021579 juice concentrates Nutrition 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000013923 monosodium glutamate Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000008635 plant growth Effects 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 235000015170 shellfish Nutrition 0.000 description 2
- 235000011888 snacks Nutrition 0.000 description 2
- 229940073490 sodium glutamate Drugs 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 238000013222 sprague-dawley male rat Methods 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 229940062776 zinc aspartate Drugs 0.000 description 2
- POEVDIARYKIEGF-CEOVSRFSSA-L zinc;(2s)-2-aminobutanedioate;hydron Chemical compound [Zn+2].[O-]C(=O)[C@@H](N)CC(O)=O.[O-]C(=O)[C@@H](N)CC(O)=O POEVDIARYKIEGF-CEOVSRFSSA-L 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 241000234282 Allium Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 101710110315 Bacchus Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 101100284769 Drosophila melanogaster hemo gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000230999 Lithothamnion Species 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- UAMAOYCLIREHSY-VMKVGKSTSA-H N[C@@H](CCC(=O)[O-])C(=O)[O-].N[C@@H](CCC(=O)[O-])C(=O)[O-].[Fe+6].N[C@@H](CC(=O)[O-])C(=O)[O-] Chemical compound N[C@@H](CCC(=O)[O-])C(=O)[O-].N[C@@H](CCC(=O)[O-])C(=O)[O-].[Fe+6].N[C@@H](CC(=O)[O-])C(=O)[O-] UAMAOYCLIREHSY-VMKVGKSTSA-H 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000218476 Phymatolithon calcareum Species 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- CPGKMLVTFNUAHL-UHFFFAOYSA-N [Ca].[Ca] Chemical compound [Ca].[Ca] CPGKMLVTFNUAHL-UHFFFAOYSA-N 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003749 cleanliness Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000000490 cosmetic additive Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000007882 dietary composition Nutrition 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003646 hair health Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 1
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229910001510 metal chloride Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- SFMJNHNUOVADRW-UHFFFAOYSA-N n-[5-[9-[4-(methanesulfonamido)phenyl]-2-oxobenzo[h][1,6]naphthyridin-1-yl]-2-methylphenyl]prop-2-enamide Chemical compound C1=C(NC(=O)C=C)C(C)=CC=C1N1C(=O)C=CC2=C1C1=CC(C=3C=CC(NS(C)(=O)=O)=CC=3)=CC=C1N=C2 SFMJNHNUOVADRW-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 229940116257 pepper extract Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 239000005297 pyrex Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/76—Metal complexes of amino carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
해조 칼슘 | 유청 칼슘 | |
칼슘 | 34% | 26.4%(26.4%) |
마그네슘 | 3.2% | 1.26%(0.447%) |
황 | 0.3% | - |
나트륨 | 0.2% | 2.6%(0.234%) |
인 | 0.06% | 14.6% |
철 | 0.08% | 0.00815% |
칼륨 | 0.04% | 0.165%(0.14%) |
망간 | 70 ppm | - |
붕소 | 25 ppm | - |
요오드 | 20 ppm | - |
아연 | 22 ppm | - |
셀레늄 | 1 ppm | - |
성분 | 함량 |
칼슘 | 7% |
마그네슘 | 1% |
칼륨 | 2.1% |
나트륨 | 1% |
알루미늄 | 25 ppm |
망간 | 25 ppm |
철 | 20 ppm |
아연 | 10 ppm |
바륨 | 4 ppm |
카드늄, 크롬, 몰리브덴, 코발트 | 5 ppm 미만 |
평가항목평가대상 | 맛 | 외관 | 종합적 평가 | |||
쓴 맛 | 텁텁한 맛 | 떫은 맛 | 색깔 | 청정도 | ||
대조군 (미에로화이바) | 12(+) | 10(+) | 11(+) | 46(++++) | 48(++++) | 48(++++) |
실시예 1의킬레이트 화합물 | 14(+) | 12(+) | 11(+) | 48(++++) | 47(++++) | 47(++++) |
성분 | 함량 |
식물성 단백 가수분해물 (질소함량 3%) | 10% |
참치자숙 농축액 | 4% |
액상당류 | 6% |
정제수 | 50% |
정제염 | 8% |
실시예 1의 화합물 | 10% |
설탕 | 5% |
잔탄검 | 0.3% |
5-뉴클레오타이드 | 0.5% |
양파즙 농축액 | 2% |
마늘즙 농축액 | 1% |
쇠고기 농축액 | 1% |
정제우지 | 1% |
주정 | 0.7% |
수용성 후추 추출액 | 0.5% |
성분 | 함량 |
액상 과당 | 5% |
폴리덱스트로스 | 1% |
구연산 | 5% |
비타민C | 0.02% |
실시예 9의 화합물 | 2% |
오렌지 과즙 농축액 | 25% |
물 | 67% |
성분 | 함량 |
1,3-butylene glycol | 5% |
glycerine | 5% |
EDTA-2Na | 0.02% |
trimethylglycine | 2.0% |
cetanol | 1.0% |
glyceryl monostearate emulsifier | 1.0% |
polysorbate 60 | 1.2% |
sorbitan sesquioleate | 0.3% |
cetyl 2-ethyl-hexaoate | 4.0% |
squalane | 5.0% |
dimethicone | 0.3% |
glyceryl stearate | 0.5% |
carbomer | 0.15% |
triethanoamine | 0.5% |
imidazolidinyl urea | 0.2% |
실시예8 | 2.0% |
정제수 | 71.8% |
성분 | 함량 |
1,3-butylene glycol | 4.0% |
dipropylene glycol | 5.0% |
EDTA-2Na | 0.02% |
octyldodeceth-16 | 0.3% |
PEG60 hydrogenate castor oil | 0.2% |
실시예 8의 화합물 | 0.5% |
정제수 | 90% |
정상군(Normal) | 실험군 | ||||
Ca-free | CaCO3 | Asp-Ca | SW-Ca | ||
Casein | 200 | 200 | 200 | 200 | 200 |
Sucrose | 100 | 100 | 100 | 100 | 100 |
Cellulose | 50 | 50 | 50 | 50 | 50 |
Mineral mix1) | 35 | 35 | 35 | 35 | 35 |
Vitamin mix | 10 | 10 | 10 | 10 | 10 |
DL-methione | 3 | 3 | 3 | 3 | 3 |
Choline bitartrate | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 |
Corn starch | 549.5 | 549.5 | 549.5 | 549.5 | 549.5 |
Corn oil | 50 | 50 | 50 | 50 | 50 |
구강투여(㎎/day) | |||||
CaCO340% | - | - | 80 | - | - |
Asp-Ca 10.8% | - | - | - | 320 | - |
Seaweed Ca 33% | - | - | - | - | 97 |
Liver(mg/BW) | Kidney(mg/BW) | Spleen(mg/BW) | |
Normal | 44.75±1.89a | 8.50±0.29ns | 3.50±0.50ns |
Ca-free | 40.67±1.41ab | 8.83±0.31 | 3.00±0.00 |
CaCO3 | 37.40±1.63b | 8.60±0.40 | 3.00±0.00 |
Asp-Ca | 44.17±1.68a | 8.40±0.26 | 3.00±0.00 |
SW-Ca | 36.00±0.63b | 8.20±0.20 | 3.00±0.32 |
비골 무게(g) | 비골 길이(mm) | |
Normal | 0.403±0.015a | 32.28±0.44ns |
Ca-free | 0.272±0.032b | 29.01±1.06 |
CaCO3 | 0.332±0.033ab | 30.03±1.10 |
Asp-Ca | 0.327±0.031ab | 30.88±1.87 |
SW-Ca | 0.292±0.043b | 28.83±1.49 |
Serum | Urine | |
(mg/dl) | ||
Normal | 10.68±0.18a | 0.20±0.03b |
Ca-free | 8.12±0.52b | 0.11±0.03c |
CaCO3 | 9.13±0.21b | 0.22±0.01b |
Asp-Ca | 10.63±0.21a | 0.22±0.04b |
SW-Ca | 10.44±0.07a | 0.32±0.02a |
Serum(mg/dl) | |
Normal | 12.19±0.38a |
Ca-free | 8.60±0.51b |
CaCO3 | 8.52±0.27b |
Asp-Ca | 11.24±0.85a |
Ca intake(mg/3days) | Fecal Ca excretion(mg/3days) | Apparent absorption(%) | |
Ca-free | 0 | 2.69 | - |
CaCO3 | 96 | 98.68 | -2.79 |
Asp-Ca | 96 | 35.39 | 58.96 |
SW-Ca | 96 | 71.05 | 25.98 |
정상군(Normal) | 실험군 | |||
Fe-free | Heme | Fe-aa | ||
Casein | 200 | 200 | 200 | 200 |
Sucrose | 100 | 100 | 100 | 100 |
Cellulose | 50 | 50 | 50 | 50 |
Mineral mix1) | 35 | 35 | 35 | 35 |
Vitamin mix | 10 | 10 | 10 | 10 |
DL-methione | 3 | 3 | 3 | 3 |
Choline bitartrate | 2.5 | 2.5 | 2.5 | 2.5 |
Corn starch | 549.5 | 549.5 | 549.5 | 549.5 |
Corn oil | 50 | 50 | 50 | 50 |
구강투여(mg/㎖/day) | ||||
1% heme | - | - | 50 | - |
10% Fe-aa | - | - | - | 5 |
Liver(mg/BW) | Kidney(mg/BW) | Spleen(mg/BW) | |
Normal | 39.25±0.85ab | 7.50±0.29ns | 3.00±0.41ns |
Fe-free | 39.90±0.90ab | 7.30±0.21 | 2.70±0.15 |
Heme | 36.90±1.06b | 7.20±0.13 | 2.78±0.15 |
Fe-aa | 40.60±1.00a | 7.50±0.22 | 3.00±0.15 |
IRON | TIBC | |
(㎍/dl) | ||
Normal | 224.50±33.65a | 662.75±17.02c |
Control | 96.13±10.27c | 841.90±13.90a |
Heme | 190.25±28.96ab | 824.63±11.60a |
Fe-aa | 137.63±23.57bc | 735.44±9.30b |
RBC(x 106/mm3) | WBC(x 103/mm3) | Hb(g/dL) | HCT(%) | |
Normal | 7.47±0.16ns | 6.13±0.50b | 13.96±0.42a | 44.20±1.43a |
Fe-free | 6.90±0.20 | 7.55±0.36a | 11.18±0.38c | 35.40±1.28b |
Heme | 7.01±0.16 | 6.12±0.37b | 11.17±0.28c | 36.11±0.89b |
Fe-aa | 7.32±0.35 | 6.02±0.46b | 12.71±0.49b | 39.33±1.86b |
Fe intake(ug/3days) | Fecal Fe excretion(ug/3days) | Apparent absorption(%) | |
Ca-free | 0 | 247.4 | - |
Heme | 1,500 | 1427.4 | 4.86 |
Fe-aa | 1,500 | 1000.6 | 33.33 |
Claims (18)
- 천연 또는 비천연의 금속 탄산염(metallic carbonate)과 산성 아미노산을 수용액 중에서 반응시키는 과정을 포함하는 것으로 구성되어 있는 아미노산 킬레이트의 제조방법.
- 제 1 항에 있어서,상기 금속 탄산염은 탄산칼슘, 탄산구리, 탄산아연, 탄산철, 탄산코발트, 탄산크롬, 탄산마그네슘, 탄산망간 등에서 선택된 2가 또는 그이상의 원자가를 가진 하나 또는 둘 이상의 탄산염이고;상기 산성 아미노산은 글루타민산, 아스파르트산 등에서 선택된 하나 또는 그 이상의 혼합물인 것을 특징으로 하는 제조방법.
- 제 1 항에 있어서, 상기 금속 탄산염은 천연의 금속 탄산염인 것을 특징으로 하는 제조방법.
- 제 2 항에 있어서, 상기 금속 탄산염은 탄산칼슘인 것을 특징으로 하는 방법.
- 제 4 항에 있어서, 상기 탄산칼슘은 해조칼슘, 난각칼슘, 패각칼슘, 갑오징어칼슘 등의 천연 소재에서 얻어지는 것을 특징으로 하는 방법.
- 제 2 항에 있어서, 상기 산성 아미노산은 글루타민산, 아스파르트산, 또는 이들의 혼합물인 것을 특징으로 하는 방법.
- 제 1 항에 있어서,상기 금속 탄산염과 산성 아미노산의 반응 부가량은, 몰비(금속 탄산염: 산성 아미노산)로 1 : 1 내지 1 : 4이고;반응온도는 0 내지 100℃이며;반응 pH는 반응종료시에 4 내지 7로 조절하는 것을 특징으로 하는 제조방법.
- 제 7 항에 있어서, 상기 pH 는 4.5 내지 6.5 인 것을 특징으로 하는 제조방법.
- 제 1 항에 있어서, 상기 반응의 개시와 동시에, 또는 반응 중에, 또는 반응 종료 후에 금속 황산염을 더 부가하여 반응시키는 것을 특징으로 하는 제조방법.
- 제 9 항에 있어서, 상기 금속 황산염은 아미노산과 금속 탄산염의 반응 중 또는 그것의 반응 후에 부가하여 반응시키는 것을 특징으로 하는 제조방법.
- 제 9 항에 있어서, 상기 금속 황산염은 황산칼슘, 황산마그네슘, 황산아연, 황산구리, 황산철, 황산망간, 황산크롬, 황산코발트 등에서 선택된 하나 또는 둘 이상의 황산염이며, 금속 탄산염의 금속이온과 다른 금속이온을 포함하고 있는 것을 특징으로 하는 제조방법.
- 제 9 항에 있어서, 상기 금속 황산염의 반응 부가량은 금속 탄산염에 기반한 아미노산 킬레이트에 대하여 1:1 내지 1:4의 몰비(금속 황산염: 금속 탄산염 기반 아미노산 킬레이트)의 범위내에 있는 것을 특징으로 하는 제조방법.
- 제 1 항에 따른 제조방법으로 제조되는 하기 화학식 1 또는 화학식 2의 아미노산 킬레이트.M(AA)2(1)M'(AA)3(2)상기 식에서, M 은 2가 금속이온이고, M' 는 3가 금속이온이며, AA 는 아미노산이다.
- 제 13 항에 있어서, 상기 아미노산 킬레이트는, 칼슘 글루타메이트/아스파테이트(calcium glutamate/aspartate), 칼슘 비스글루타메이트(calcium bisglutamate), 칼슘 비스아스파테이트(calcium bisaspartate), 구리글루타메이트/아스파테이트(cooper glutamate/aspartate), 구리 비스글루타메이트(cooper bisglutamate), 구리 비스아스파테이트(cooper bisaspartate), 아연 글루타메이트/아스파테이트(zinc glutamate/aspartate), 아연 비스글루타메이트(zinc bisglutamate), 아연 비스아스파테이트(zinc bisaspartate), 철 글루타메이트/아스파테이트(iron glutamate/aspartate), 철 비스글루타메이트(iron bisglutamate), 철 비스아스파테이트(iron bisaspartate), 철 비스글루타메이트/아스파테이트(iron bisglutamate/aspartate), 철 글루타메이트/비스아스파테이트(iron glutamate/ bisaspartate), 크롬 글루타메이트/아스파테이트(chromium glutamate/aspartate), 크롬 비스글루타메이트(chromium bisglutamate), 크롬 비스아스파테이트(chromium bisaspartate), 크롬 비스글루타메이트/아스파테이트(chromium bisglutamate/aspartate), 크롬 글루타메이트/비스아스파테이트(chromium glutamate/ bisaspartate), 코발트 글루타메이트/아스파테이트(covalt glutamate/aspartate), 코발트 비스글루타메이트(covalt bisglutamate), 코발트 비스아스파테이트(covalt bisaspartate), 마그네슘 글루타메이트/아스파테이트(magnesium glutamate/aspartate), 마그네슘 비스글루타메이트(magnesium bisglutamate), 마그네슘 비스아스파테이트(magnesium bisaspartate), 망간 글루타메이트/아스파테이트(manganese glutamate/aspartate), 망간 비스글루타메이트(manganese bisglutamate), 망간 비스아스파테이트(manganese bisaspartate) 등으로 이루어진 군에서 선택되는 하나 또는 둘 이상인 것을 특징으로 하는 아미노산 킬레이트.
- 유효성분으로서, 제 13 항에 따른 화학식 1 또는 2 의 아미노산 킬레이트를 약제학적 또는 식품영양학적 또는 화장학적 유효량으로 함유하는 조성물.
- 제 15 항에 있어서, 상기 조성물은 약학적으로 허용되는 담체를 포함하는 약제 조성물인 것을 특징으로 하는 조성물.
- 제 15 항에 있어서, 상기 조성물은 식품영양학적으로 허용되는 담체를 포함하는 식품 또는 음료 조성물인 것을 특징으로 하는 조성물.
- 제 15 항에 있어서, 상기 조성물은 화장학적으로 허용되는 담체를 포함하는 화장품 조성물인 것을 특징으로 하는 조성물.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20020076803 | 2002-12-05 | ||
KR1020020076803 | 2002-12-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20040049294A true KR20040049294A (ko) | 2004-06-11 |
KR100470763B1 KR100470763B1 (ko) | 2005-02-21 |
Family
ID=36165424
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2003-0088214A KR100470763B1 (ko) | 2002-12-05 | 2003-12-05 | 아미노산 킬레이트의 제조방법 |
Country Status (7)
Country | Link |
---|---|
US (2) | US7375243B2 (ko) |
EP (1) | EP1569943A4 (ko) |
JP (1) | JP4639086B2 (ko) |
KR (1) | KR100470763B1 (ko) |
CN (1) | CN100549015C (ko) |
AU (1) | AU2003302660A1 (ko) |
WO (1) | WO2004050664A1 (ko) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100927958B1 (ko) * | 2006-07-13 | 2009-11-24 | 주식회사 머젠스 | 금속의 흡수를 촉진시키는 금속-산성아미노산 킬레이트를함유하는 조성물 |
KR101046905B1 (ko) * | 2006-12-25 | 2011-07-07 | 아지노모토 가부시키가이샤 | 염기성 아미노산 염산염 결정의 수득 방법 |
KR101509239B1 (ko) * | 2006-02-03 | 2015-04-06 | 제이알 케미칼즈 | 화학적 조성물 및 그의 제조방법 |
CN104529646A (zh) * | 2015-01-06 | 2015-04-22 | 上海红辉化工有限公司 | 一种螯合微量元素肥料及其制备方法 |
WO2019112383A1 (ko) * | 2017-12-08 | 2019-06-13 | 윤주석 | 금속 미네랄 디아미네이트 및 이의 제조방법 |
KR20190068463A (ko) * | 2017-12-08 | 2019-06-18 | 주식회사 휴엔 | 금속 미네랄 디아미네이트 및 이의 제조방법 |
KR20190095091A (ko) * | 2018-12-07 | 2019-08-14 | 주식회사 바이오에이엠 | 동물사료첨가제 및 이의 제조방법 |
KR20200011994A (ko) * | 2017-11-28 | 2020-02-04 | (주)비티엔 | 아연 아스파르트산 복합체, 및 이를 포함하는 면역 증강용 약학 조성물 |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1571198A1 (en) * | 2004-03-02 | 2005-09-07 | Dalli-Werke GmbH & Co. KG. | Polymer bound manganese compounds in cleaning compositions |
US20050235718A1 (en) * | 2004-04-21 | 2005-10-27 | Kevin Dickinson | Organic amino acid chelates, methods for making such chelates, and methods for using such chelates |
JP5167594B2 (ja) * | 2005-03-28 | 2013-03-21 | 大正製薬株式会社 | 銅化合物配合内服液用組成物 |
AR055285A1 (es) * | 2005-11-11 | 2007-08-15 | Edgardo Adrian Hager | Sales de nutrientes minerales estabilizados con aminoacidos productos y suplemento alimenticio que las comprenden y procedimientos de obtencion |
US8007846B2 (en) * | 2006-01-18 | 2011-08-30 | Albion International, Inc. | Mixed amino acid/mineral compounds having improved solubility |
US20070269495A1 (en) * | 2006-05-18 | 2007-11-22 | Ashmead H Dewayne | Compositions and methods for enhancing mineral levels in animals with reduced environmental impact |
EP2162153B1 (en) * | 2007-06-06 | 2016-03-30 | Novus International Inc. | Dietary supplements for promotion of growth, repair, and maintenance of bone and joints |
CN101602685B (zh) * | 2009-06-30 | 2012-06-27 | 青岛大学 | 以贝类加工废弃物为钙源的谷氨酸螯合钙合成方法 |
CN101756042B (zh) * | 2010-03-12 | 2012-07-04 | 广州英赛特生物技术有限公司 | 谷氨酸铜或其衍生物作为动物促生长饲料添加剂的应用 |
CN101822316A (zh) * | 2010-03-12 | 2010-09-08 | 广州英赛特生物技术有限公司 | 谷氨酸微量元素螯合物作为动物饲料添加剂的应用 |
CN101785534B (zh) * | 2010-03-12 | 2013-06-12 | 广州英赛特生物技术有限公司 | 谷氨酸锌或其衍生物作为动物促生长饲料添加剂的应用 |
CN102127144A (zh) * | 2011-04-14 | 2011-07-20 | 兰州理工大学 | 纽甜-钙的螯合物及其制备方法 |
CN102627583A (zh) * | 2012-03-22 | 2012-08-08 | 广州九益生物技术有限公司 | N-氨基甲酰-l-谷氨酸铜络合物及其制备方法 |
JP5990029B2 (ja) * | 2012-04-17 | 2016-09-07 | 公益財団法人ひょうご科学技術協会 | 毛髪の分析法 |
CN102731331A (zh) * | 2012-06-21 | 2012-10-17 | 上海腾瑞医药技术有限公司 | 一种l-天门冬氨酸钙及其制备方法 |
CN102775340B (zh) * | 2012-06-25 | 2014-04-16 | 青岛大学 | 以贝壳为钙源的焦谷氨酸钙合成方法 |
EP2870987B1 (en) * | 2012-07-05 | 2020-01-08 | Aisin Seiki Kabushiki Kaisha | Alkali metal and/or alkali earth metal extraction method |
CN102898338A (zh) * | 2012-10-16 | 2013-01-30 | 中国科学院过程工程研究所 | 一种α-氨基酸铬(III)螯合物及其制备方法 |
CN102875402B (zh) * | 2012-10-30 | 2015-06-24 | 宜兴市前成生物有限公司 | 一种制备l-天门冬氨酸镁的方法 |
JP5687682B2 (ja) * | 2012-12-20 | 2015-03-18 | ユニチカ株式会社 | カルシウム吸収促進組成物 |
CN103626647B (zh) * | 2013-11-27 | 2015-12-02 | 青岛大学 | 以贝壳为原料的钙型干贝素合成方法 |
CN103735421B (zh) * | 2013-12-24 | 2015-09-30 | 董延昌 | 一种皮肤抗衰老组合物及其制备方法 |
CN103739509B (zh) * | 2014-01-09 | 2015-12-30 | 山东祥维斯生物科技股份有限公司 | 一种甘氨酸螯合锰的工业化生产制备工艺 |
JP6309287B2 (ja) * | 2014-01-29 | 2018-04-11 | 協和発酵バイオ株式会社 | 3−ヒドロキシ−3−メチル酪酸カルシウム含有飲料 |
CN104095242B (zh) * | 2014-07-15 | 2016-04-13 | 广州大学 | 一种复合锌硒多肽化合物及其制备方法 |
CN104326932A (zh) * | 2014-10-09 | 2015-02-04 | 中国食品发酵工业研究院 | 一种低温固相合成天门冬氨酸锌的方法 |
CN104326933A (zh) * | 2014-10-09 | 2015-02-04 | 中国食品发酵工业研究院 | 一种低温固相合成天门冬氨酸钙的方法 |
CN104402750A (zh) * | 2014-12-09 | 2015-03-11 | 芜湖莱博生物医药有限公司 | 双羧基氨基酸-铬螯合物及其制备方法 |
EP3075832B1 (en) * | 2015-03-30 | 2021-04-14 | Dalli-Werke GmbH & Co. KG | Manganese-amino acid compounds in cleaning compositions |
CN106987580B (zh) * | 2016-02-29 | 2020-11-24 | 华南理工大学 | 一种生物相容金属有机骨架材料谷氨酸-锌及其制备及应用 |
CN107417556A (zh) * | 2017-05-23 | 2017-12-01 | 王广生 | L‑天门冬氨酸螯合钙及其制备方法 |
CN107286032A (zh) * | 2017-06-20 | 2017-10-24 | 峨眉山市龙腾生物科技有限公司 | 家禽羽毛制备氨基酸螯合物的方法 |
KR102000135B1 (ko) | 2017-10-13 | 2019-10-01 | 주식회사 소프트아쿠아 | 아미노산-미네랄 복합체를 포함하는 액상 보조사료 조성물 |
KR101998583B1 (ko) | 2017-10-30 | 2019-07-11 | 주식회사 소프트아쿠아 | 활성 미네랄을 포함하는 가금류의 면역 증강용 조성물 |
US11912785B2 (en) | 2017-12-06 | 2024-02-27 | Steven W. Bailey | Peptide compositions for slowing degradation of vitamin mineral supplements, foods, pharmaceutical and cosmetics |
CN108359552B (zh) * | 2018-05-21 | 2020-06-05 | 王炳钦 | 一种保湿美白手工皂及其制备方法 |
DE102018113243A1 (de) * | 2018-06-04 | 2019-12-05 | BIOCHEM Zusatzstoffe Handels- und Produktionsgesellschaft mbH | Verfahren zur Herstellung einer Zusammensetzung enthaltend zumindest eine Metall-Aminosäure-Verbindung sowie Zusammensetzung erhältlich durch ein derartiges Verfahren |
CN109180510B (zh) * | 2018-08-29 | 2021-08-24 | 长沙兴嘉生物工程股份有限公司 | 一种高纯谷氨酸亚铁的制备方法 |
CN109081786A (zh) * | 2018-10-15 | 2018-12-25 | 禄丰天宝磷化工有限公司 | 一种氨基酸亚铁螯合物的制备方法 |
CN110256267A (zh) * | 2019-07-08 | 2019-09-20 | 中国海洋大学 | 一种以太平洋牡蛎壳为钙源的l-天冬氨酸螯合钙制备方法 |
CN110897039B (zh) * | 2019-12-26 | 2023-02-03 | 长沙兴嘉生物工程股份有限公司 | 一种缬氨酸锰的制备方法及其应用 |
CN113201801B (zh) * | 2021-04-15 | 2022-07-22 | 上海工程技术大学 | 一种氨基酸螯合锌修饰莱麻天丝纤维的制备方法和应用 |
CN113277954B (zh) * | 2021-06-17 | 2023-04-28 | 英德市匠心新材料股份有限公司 | 一种氨基酸金属螯合物微纳米粉体及其制备方法 |
CN113666836B (zh) * | 2021-08-03 | 2024-06-11 | 四川吉隆达生物科技集团有限公司 | 饲料级谷氨酸锌的生产工艺 |
CN113735729A (zh) * | 2021-08-03 | 2021-12-03 | 四川吉隆达生物科技集团有限公司 | 饲料级谷氨酸亚铁的生产工艺 |
CN118382443A (zh) * | 2021-10-05 | 2024-07-23 | 安美洛生技有限公司 | 含钴的酸性胺基酸错合物及其治疗癌症的用途 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6078950A (ja) * | 1983-10-14 | 1985-05-04 | フエルラーフアルム アルツナイミツテルフアブリーク アポテーケル ハー.ヤー.フオン エーリツヒ ゲゼルシヤフト ミツト ベシユレンクテル ハフツンク ウント コンパニー カーゲー | アミノジカルボン酸−二価金属−ハロゲン錯塩の製造法及びそれら新規錯塩 |
US4599152A (en) | 1985-05-24 | 1986-07-08 | Albion Laboratories | Pure amino acid chelates |
US4863898A (en) * | 1986-02-06 | 1989-09-05 | Albion International, Inc. | Amino acid chelated compositions for delivery to specific biological tissue sites |
US4830716B1 (en) * | 1986-07-03 | 1999-12-07 | Albion Int | Preparation of pharmaceutical grade amino acid chelates |
US5516925A (en) * | 1994-08-23 | 1996-05-14 | Albion International, Inc. | Amino acid chelates having improved palatability |
US6197815B1 (en) * | 1998-03-18 | 2001-03-06 | J.H. Biotech, Inc. | Amino acid chelates to reduce still births and increase birth weight in non-human animals |
JP3107789B2 (ja) * | 1998-09-25 | 2000-11-13 | キユーピー株式会社 | 卵殻カルシウム組成物及びその製造方法並びに該卵殻カルシウム組成物を含有する食品 |
US6169118B1 (en) * | 1998-11-12 | 2001-01-02 | Block Drug Company, Inc. | Flavor blend for masking unpleasant taste of zinc compounds |
WO2001032037A1 (en) * | 1999-11-01 | 2001-05-10 | Albion International, Inc. | Compositions and methods for calcium fortification of dairy products and oleaginous foods |
US6458981B1 (en) | 2000-10-11 | 2002-10-01 | Albion International, Inc. | Composition and method for preparing amino acid chelate hydroxides free of interfering ions |
US7129375B2 (en) * | 2002-10-16 | 2006-10-31 | Zinpro Corporation | Metal complexes of α amino dicarboxylic acids |
-
2003
- 2003-12-05 EP EP03812388A patent/EP1569943A4/en not_active Withdrawn
- 2003-12-05 WO PCT/KR2003/002674 patent/WO2004050664A1/en active Application Filing
- 2003-12-05 CN CNB2003801050987A patent/CN100549015C/zh not_active Expired - Fee Related
- 2003-12-05 US US10/537,409 patent/US7375243B2/en not_active Expired - Fee Related
- 2003-12-05 KR KR10-2003-0088214A patent/KR100470763B1/ko active IP Right Grant
- 2003-12-05 JP JP2004556973A patent/JP4639086B2/ja not_active Expired - Fee Related
- 2003-12-05 AU AU2003302660A patent/AU2003302660A1/en not_active Abandoned
-
2007
- 2007-06-29 US US12/307,611 patent/US20100093850A1/en not_active Abandoned
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101509239B1 (ko) * | 2006-02-03 | 2015-04-06 | 제이알 케미칼즈 | 화학적 조성물 및 그의 제조방법 |
KR100927958B1 (ko) * | 2006-07-13 | 2009-11-24 | 주식회사 머젠스 | 금속의 흡수를 촉진시키는 금속-산성아미노산 킬레이트를함유하는 조성물 |
KR101046905B1 (ko) * | 2006-12-25 | 2011-07-07 | 아지노모토 가부시키가이샤 | 염기성 아미노산 염산염 결정의 수득 방법 |
US8372606B2 (en) | 2006-12-25 | 2013-02-12 | Ajinomoto Co., Inc. | Methods for obtaining crystals of a basic amino acid hydrochloride |
CN104529646A (zh) * | 2015-01-06 | 2015-04-22 | 上海红辉化工有限公司 | 一种螯合微量元素肥料及其制备方法 |
KR20200011994A (ko) * | 2017-11-28 | 2020-02-04 | (주)비티엔 | 아연 아스파르트산 복합체, 및 이를 포함하는 면역 증강용 약학 조성물 |
KR20200011864A (ko) * | 2017-11-28 | 2020-02-04 | (주)비티엔 | 면역 증강 활성을 가지는 아미노산 미네랄 복합체 및 이를 포함하는 식품, 약학 또는 사료용 조성물 |
KR20200011918A (ko) * | 2017-11-28 | 2020-02-04 | (주)비티엔 | 신규 아미노산 미네랄 복합체, 및 이를 포함하는 면역 증강용 사료 또는 동물용 의약 조성물 |
KR20200011993A (ko) * | 2017-11-28 | 2020-02-04 | (주)비티엔 | 신규 아미노산 미네랄 복합체, 및 이를 포함하는 면역 증강용 식품 조성물 |
WO2019112383A1 (ko) * | 2017-12-08 | 2019-06-13 | 윤주석 | 금속 미네랄 디아미네이트 및 이의 제조방법 |
KR20190068463A (ko) * | 2017-12-08 | 2019-06-18 | 주식회사 휴엔 | 금속 미네랄 디아미네이트 및 이의 제조방법 |
KR20190095091A (ko) * | 2018-12-07 | 2019-08-14 | 주식회사 바이오에이엠 | 동물사료첨가제 및 이의 제조방법 |
Also Published As
Publication number | Publication date |
---|---|
JP2006509787A (ja) | 2006-03-23 |
JP4639086B2 (ja) | 2011-02-23 |
US20100093850A1 (en) | 2010-04-15 |
US7375243B2 (en) | 2008-05-20 |
EP1569943A4 (en) | 2007-11-28 |
EP1569943A1 (en) | 2005-09-07 |
AU2003302660A1 (en) | 2004-06-23 |
KR100470763B1 (ko) | 2005-02-21 |
CN100549015C (zh) | 2009-10-14 |
US20060128799A1 (en) | 2006-06-15 |
CN1720249A (zh) | 2006-01-11 |
WO2004050664A1 (en) | 2004-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100470763B1 (ko) | 아미노산 킬레이트의 제조방법 | |
US4315927A (en) | Dietary supplementation with essential metal picolinates | |
US5292729A (en) | II-bond aromatic vitamin chelates | |
Ashmead | The absorption and metabolism of iron amino acid chelate | |
JPH0671414B2 (ja) | 鉄ミネラル補給物 | |
Dock et al. | Cation exchangers: their use and hazards as aids in managing edema | |
Nagpal et al. | Iron formulations in pediatric practice | |
IE54572B1 (en) | Pharmaceutically active succinylated proteins comprising iron | |
US20080182896A1 (en) | Use of metal chelates in human or animal feeding | |
JP2010090064A (ja) | 純アミノ酸キレート錯体の製造方法及びその用途 | |
JP2983171B2 (ja) | ピコリン酸−クロム複合物の新たな製造方法 | |
US4208405A (en) | Trace element composition for iron deficiency anemia | |
US20040048925A1 (en) | Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives | |
EP0791357A2 (en) | Use of gluten peptides as stimulator of mineral absorption and preventive agent of hyperlipidermia and hypercholesterolemia | |
CN102579956B (zh) | 一种药物组合物及其应用 | |
JP2660906B2 (ja) | ウニ由来カルシウムの製造方法ならびにこの製造方法によって得られる易吸収性カルシウムを含有する組成物 | |
US20040220266A1 (en) | Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives | |
US20100086619A1 (en) | Dietary supplement containing strontium (M) ascorbate, compositions containing same, method for making same and method for using same | |
JPH0586932B2 (ko) | ||
US5665385A (en) | Dietary metal supplements | |
TW460285B (en) | A process for preparing calcium containing composition with high oral bioavailability | |
JP3713553B2 (ja) | アルギニンとrnaを含有する脳脊髄系神経栄養剤 | |
JP2005104953A (ja) | ミネラル補給用アルカリ水溶液、その製造方法及びそれを利用した骨多孔症予防及び改善用造成物(alkalinemineralsolution.Manufacturingmethodthereofandfoodforosteoporosispreventionusingthesame) | |
JP2006519859A (ja) | 重炭酸およびアスコルビン酸カリウムタウレート複合体 | |
JP2579593B2 (ja) | 吸収性の優れたカルシウム含有組成物を含有する健康食品、該組成物を含有する薬剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
A302 | Request for accelerated examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
J201 | Request for trial against refusal decision | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121228 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20140108 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20150113 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20161229 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20190115 Year of fee payment: 15 |
|
FPAY | Annual fee payment |
Payment date: 20200130 Year of fee payment: 16 |